Combination Approaches to the Use of G12C KRAS Inhibitors

Time: 9:00 am
day: Day One


• KRAS G12C inhibitors have proved effective on many G12C KRAS mutant tumour in vitro, in vivo and in clinical trials, but acquired and pre-existing resistance is a problem

• Several approaches have been taken to establish how best to combine these drugs for more effective treatment of KRAS G12C mutant cancers and minimisation of resistance

• The response of KRAS G12C mutant lung tumour with these inhibitors profoundly alters the tumour immune microenvironment, allowing ingression of various effector immune cells: studying the phenotype of these cells suggests optimal combinations between KRAS G12C inhibitors and immunotherapies